Research to know,
know to prevent and cure

Last video

Posición de los trocares para cirugía laparoscópica y robótica de riñón y pélvica de acuerdo a la anatomía

View all videos

Week Article

  • Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care

    Cabozantinib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of patients with advanced renal cell carcinoma (RCC) at a dose of 60 mg/day. As with other TKIs, cabozantinib is associated with high interpatient variability in drug clearance and exposure that can significantly impact safety and tolerability across a patient population. To optimize cabozantinib exposure (maintaining efficacy and tolerability) for the individual, patients may require treatment interruption with dose reduction (40 mg/day and then 20 mg/day). ...

View all articles

About us

The LARCG (Latin American Renal Cancer Group) is a group of scientific and educational, multicentric, multidisciplinary and independent. It is not for profit, and the term of operation is indeterminate. It consists of Urologists, Pathologists and Oncologists, as well as professionals and researchers related to the field of health, belonging to Hospitals in Latin America, Spain and the United States.

Read more

Last Tweets

@DrChoueiri presents Cabo/Nivo vs Sutent @myESMO #ESMO2020 @OncoAlert @tompowles1 @montypal @neerajaiims @OncoAlert am watching via @TiansterZhang chat! Exciting data of another VEGF TKI & IO combo! What is your preferred 1L combo in RCC? Cabo/Nivo or Pembro/Axi or Ipi/Nivo?

4

Just in @KCA_Journal 👉🏻1/3rd patients with mRCC kidneycancer have bone mets. Scant data on development, prevention, prognosis and treatment of skeletal related events (SREs) in mRCC👉🏻Excellent systemic review by @PBarataMD @bilenma & team. @KidneyCancer https://t.co/Q6FoU859BQ

3

Not typical for an #oncologist to sift through @NatRevNeph so leading my friends towards this DEFINITIVE article on #kidneycancer biomarkers written from start to finish by @NazliDizman, a resident now at @YaleMedicine. Please have a look! @neerajaiims @DrChoueiri @kamkalantar https://t.co/lj7XnQIAfF

Load More...

Sponsor

Associates

You don't have permission to register